{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glomerular+Disease&page=2",
    "query": {
      "condition": "Glomerular Disease",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glomerular+Disease&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:13:48.229Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06466135",
      "title": "Study of WAL0921 in Patients With Glomerular Kidney Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Nephropathies",
        "Primary Focal Segmental Glomerulosclerosis",
        "Minimal Change Disease",
        "Primary Immunoglobulin A Nephropathy",
        "Primary Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "WAL0921",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walden Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 96,
      "start_date": "2024-07-02",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-05-22T05:13:48.229Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hinsdale",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06466135"
    },
    {
      "nct_id": "NCT05067127",
      "title": "Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "C3G",
        "IC-MPGN",
        "C3 Glomerulopathy",
        "C3 Glomerulonephritis",
        "Complement 3 Glomerulopathy",
        "Complement 3 Glomerulopathy (C3G)",
        "Complement 3 Glomerulonephritis",
        "Dense Deposit Disease",
        "DDD",
        "Membranoproliferative Glomerulonephritis",
        "Membranoproliferative Glomerulonephritis (MPGN)",
        "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2021-11-12",
      "completion_date": "2025-01-14",
      "has_results": true,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-05-22T05:13:48.229Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05067127"
    },
    {
      "nct_id": "NCT05809531",
      "title": "An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "C3G",
        "IC-MPGN",
        "C3 Glomerulopathy",
        "C3 Glomerulonephritis",
        "Complement 3 Glomerulopathy",
        "Complement 3 Glomerulopathy (C3G)",
        "Complement 3 Glomerulonephritis",
        "Dense Deposit Disease",
        "DDD",
        "Membranoproliferative Glomerulonephritis",
        "Membranoproliferative Glomerulonephritis (MPGN)",
        "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2023-05-29",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-05-22T05:13:48.229Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Gainsville, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainsville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05809531"
    },
    {
      "nct_id": "NCT05065970",
      "title": "Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A (IgA) Nephropathy"
      ],
      "interventions": [
        {
          "name": "Felzartamab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "HI-Bio, A Biogen Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-08-31",
      "completion_date": "2024-05-06",
      "has_results": true,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-05-22T05:13:48.229Z",
      "location_count": 4,
      "location_summary": "Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Vacaville",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05065970"
    },
    {
      "nct_id": "NCT07225387",
      "title": "Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "Voclosporin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NephroNet, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2024-10-01",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-05-22T05:13:48.229Z",
      "location_count": 7,
      "location_summary": "Glendale, Arizona • Atlanta, Georgia • Lawrenceville, Georgia + 3 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07225387"
    },
    {
      "nct_id": "NCT00001392",
      "title": "Pathogenesis of Glomerulosclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glomerular Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 537,
      "start_date": "1996-04-16",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-05-22T05:13:48.229Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001392"
    },
    {
      "nct_id": "NCT00625820",
      "title": "Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Disease",
        "Albuminuria"
      ],
      "interventions": [
        {
          "name": "6R BH4",
          "type": "DRUG"
        },
        {
          "name": "Vitamin C",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 17,
      "start_date": "2008-05",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2016-10-18",
      "last_synced_at": "2026-05-22T05:13:48.229Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00625820"
    },
    {
      "nct_id": "NCT03955445",
      "title": "Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "C3 Glomerulopathy",
        "Immune-complex-membranoproliferative Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "LNP023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 225,
      "start_date": "2019-10-03",
      "completion_date": "2036-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-05-22T05:13:48.229Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03955445"
    },
    {
      "nct_id": "NCT05781750",
      "title": "A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "zetomipzomib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kezar Life Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2023-11-03",
      "completion_date": "2024-11-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-05-22T05:13:48.229Z",
      "location_count": 4,
      "location_summary": "Lake Charles, Louisiana • East Providence, Rhode Island • Colleyville, Texas + 1 more",
      "locations": [
        {
          "city": "Lake Charles",
          "state": "Louisiana"
        },
        {
          "city": "East Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Colleyville",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05781750"
    },
    {
      "nct_id": "NCT07547878",
      "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Finerenone",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Lotensin",
          "type": "DRUG"
        },
        {
          "name": "Capoten",
          "type": "DRUG"
        },
        {
          "name": "Enalapril",
          "type": "DRUG"
        },
        {
          "name": "Monopril",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril",
          "type": "DRUG"
        },
        {
          "name": "Univasc",
          "type": "DRUG"
        },
        {
          "name": "Aceon",
          "type": "DRUG"
        },
        {
          "name": "Accupril",
          "type": "DRUG"
        },
        {
          "name": "Altace",
          "type": "DRUG"
        },
        {
          "name": "Mavik",
          "type": "DRUG"
        },
        {
          "name": "Edarbi",
          "type": "DRUG"
        },
        {
          "name": "Atacand",
          "type": "DRUG"
        },
        {
          "name": "Avapro",
          "type": "DRUG"
        },
        {
          "name": "Cozaar",
          "type": "DRUG"
        },
        {
          "name": "Benicar",
          "type": "DRUG"
        },
        {
          "name": "Micardis",
          "type": "DRUG"
        },
        {
          "name": "Diovan",
          "type": "DRUG"
        },
        {
          "name": "Invokana",
          "type": "DRUG"
        },
        {
          "name": "Farxiga",
          "type": "DRUG"
        },
        {
          "name": "Jardiance",
          "type": "DRUG"
        },
        {
          "name": "Ertugliflozin",
          "type": "DRUG"
        },
        {
          "name": "Brenzavvy",
          "type": "DRUG"
        },
        {
          "name": "Sotagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 64,
      "start_date": "2026-04-30",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-05-22T05:13:48.229Z",
      "location_count": 1,
      "location_summary": "Temple, Texas",
      "locations": [
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07547878"
    }
  ]
}